ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

被引：1
|
作者：
Zammarchi, Francesca
Chivers, Simon
Havenith, Karin
Williams, David G.
Adams, Lauren
Mellinas-Gomez, Maria
Corbett, Simon
Tyrer, Peter
D'Hooge, Francois
Cho, Song
Dimasi, Nazzareno
Hinrichs, Mary Jane
Howard, Phil W.
Hartley, John A.
van Berkel, Patrick H.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3111A
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3111A
引用
收藏
页数：2
相关论文
共 38 条
  • [21] Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
    Petrylak, Daniel P.
    Kantoff, Philip
    Vogelzang, Nicholas J.
    Mega, Anthony
    Fleming, Mark T.
    Stephenson, Joe J., Jr.
    Frank, Richard
    Shore, Neal D.
    Dreicer, Robert
    McClay, Edward F.
    Berry, William R.
    Agarwal, Manish
    DiPippo, Vincent A.
    Rotshteyn, Yakov
    Stambler, Nancy
    Olson, William C.
    Morris, Stephen A.
    Israel, Robert J.
    PROSTATE, 2019, 79 (06): : 604 - 613
  • [22] A novel pegylated biparatopic antibody-drug conjugate (pb-adc) targeting cancers with low HER2+ expression
    Liu, Shumin
    Yin, Shuqiang
    Lyu, Weidong
    Lei, Yang
    Zhuo, Qiudong
    Wu, Zibin
    Tan, Shuangyu
    Zheng, Liling
    Wen, Yu
    Wu, David
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2
    Wichmann, Christian Werner
    Burvenich, Ingrid Julienne Georgette
    Guo, Nancy
    Rigopoulos, Angela
    McDonald, Alexander
    Cao, Diana
    O'Keefe, Graeme Joseph
    Gong, Sylvia Jie
    Gan, Hui Kong
    Scott, Fiona Elizabeth
    Pore, Nabendu
    Coats, Steven
    Scott, Andrew Mark
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 122
  • [24] hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.
    Zammarchi, Francesca
    Corbett, Simon
    Adams, Lauren
    Mellinas-Gomez, Maria
    Tyrer, Peter
    Dissanayake, Sandamali
    Sims, Simone
    Havenith, Karin
    Chivers, Simon
    Willimas, David G.
    Howard, Philip W.
    Hartley, John A.
    van Berkel, Patrick
    BLOOD, 2016, 128 (22)
  • [25] A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47
    Liu, Shumin
    Lyu, Weidong
    Yin, Shuqiang
    Lei, Yang
    Zhuo, Qiudong
    Zheng, Liling
    Sun, Bin
    Tan, Shuangyu
    Jiang, Lidong
    Zhang, Teng
    Gao, Bo
    Xu, Rui
    Huang, Dechang
    Li, Yong
    Wu, Zibin
    Wu, David
    Wen, Yvonne Yu
    CANCER RESEARCH, 2023, 83 (07)
  • [26] CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies
    Li, Fu
    Li, Yongwang
    Zhang, Lan
    Zhang, Clarence K.
    Hu, Hui-Han A.
    Zhang, Juan
    Pan, Ying
    Jung, Jinwon
    Lee, Sang Hoon
    Ryu, Hyun-Min
    Park, Yun-Hee
    Yu, Haixiang
    Tse, Archie N.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [27] Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
    Tsang, Nicola
    Veillard, Nicolas
    Horsley, Elizabeth
    Havenith, Karin
    Janghra, Narinder
    Zaitseva, Kristina
    Oblette, Cecile
    Kirby, Ian
    Hogg, Paul W.
    Zammarchi, Francesca
    de Haan, Lolke
    van Berkel, Patrick H.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Kahl, Brad S.
    Hamadani, Mehdi
    Radford, John
    Carlo-Stella, Carmelo
    Caimi, Paolo
    Reid, Erin
    Feingold, Jay M.
    Ardeshna, Kirit M.
    Solh, Melhem
    Heffner, Leonard T.
    Ungar, David
    He, Shui
    Boni, Joseph
    Havenith, Karin
    O'Connor, Owen A.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6986 - 6994
  • [29] Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers
    Zammarchi, Francesca
    Chivers, Simon
    van Berkel, Patrick
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
    Starodub, Alexander
    Ocean, Allyson J.
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Salim Samuel
    Messersmith, Wells A.
    Shah, Manlsh A.
    Vandat, Linda T.
    Chuang, Ellen
    Lin, Bruce S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
1234